Study Results: Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Updated Results from Phase 2 EPCORE NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting - Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient setting - Adverse event profile and efficacy were consistent with previously reported studies in R/R DLBCL patients - Data also demonstrated 64.3% overall response rate with a complete response rate of 47.6% in patients treated with epcoritamab following one prior line of systemic DLBCL therap